EUVIMEDEUVIMED entdecken
Crossref

Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices

Amanda Sowder iD, Ayesha Ather, Emma Birks, Andrew Kolodziej, Rajasekhar Malyala, Adam Sieg, Aric Schadler, Rachel Unger, Maya Guglin, William Kuan

Artificial Organs · 2023

DOI: 10.1111/aor.14565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2023. Verfasst von Amanda Sowder und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University of Kentucky Healthcare, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Stroke, Thrombosis, Heart Failure. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The HeartMate3 left ventricular assist device (HM3 LVAD) has shown a low incidence of thrombosis, but bleeding risk is as high as 43%. We aim to describe the impact of lower international normalization ratio (INR) goal on clinical outcomes.

Methods

In February 2019, our tertiary care institution lowered INR goal in HM3 patients from manufacturer recommendations to 1.8–2.2 and retrospectively analyzed the data. Two cohorts were compared: patients with lower INR goal upon implant (De novo) and those with subsequently lowered INR goal (Adjusted). The Adjusted group also served as its own historical control. Both groups continued aspirin 81 milligrams daily per manufacturer recommendations. The primary outcomes were incidences of bleed and thrombosis events within 12 months. Secondary outcomes included survival free of disabling stroke or reoperation to remove or replace the device and Rosendaal time in therapeutic range (TTR) over 12 months.

Results

Thirty‐one patients were evaluated for inclusion with 26 meeting criteria. Within 12 months, incidence of bleeding events was 25% and 28.6% in the De novo and Adjusted groups, respectively. Incidence of thrombotic events within 12 months was 0% in the De novo group and 7.1% in the Adjusted group. Twelve‐month survival free of disabling stroke or reoperation to remove or replace the device was higher over 12 months for patients in the De novo group (91.7% vs. 78.6%). Median 12‐month TTR was 36%, which was primarily attributable to subtherapeutic deviations.

Conclusions

A lower INR goal may be safe when initiated De novo following implantation of the HM3. This study informs the need for larger prospective studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesStrokeThrombosisHeart FailureHumansInternational Normalized RatioProspective StudiesRetrospective StudiesGoalsHemorrhage

Stichwörter der Autor:innen

advanced heart failureanticoagulationleft ventricular assist devicewarfarin

Autor:innen und Institutionen

  • Department of Cardiology, University of Kentucky Healthcare, Lexington, Kentucky, USA.
  • Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
  • Department of Cardiology, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
  • Department of Cardiology, Indiana University Health, Indianapolis, Indiana, USA.

ORCID-Profile: Amanda Sowder

Zitieren

APA

Sowder, A., Ather, A., Birks, E., Kolodziej, A., Malyala, R., Sieg, A., Schadler, A., Unger, R., Guglin, M., & Kuan, W. (2023). Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices. Artificial Organs. https://doi.org/10.1111/aor.14565

Vancouver

Sowder A, Ather A, Birks E, Kolodziej A, Malyala R, Sieg A, et al. Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices. Artificial Organs. 2023. doi:10.1111/aor.14565

BibTeX
@article{Sowder2023,
  author = {Sowder, Amanda and Ather, Ayesha and Birks, Emma and Kolodziej, Andrew and Malyala, Rajasekhar and Sieg, Adam and Schadler, Aric and Unger, Rachel and Guglin, Maya and Kuan, William},
  title = {Evaluation of adjusted international normalized ratio goal in patients with HeartMate 3 left ventricular assist devices},
  journal = {Artificial Organs},
  year = {2023},
  doi = {10.1111/aor.14565}
}
Kostenlos starten →